2024-01-26 09:13:32 ET
Summary
- Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024.
- The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article.
- The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks